Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Needham analyst Gil Blum upgraded Amicus Therapeutics, Inc. FOLD from Hold to Buy and announced a $14 price target. Amicus Therapeutics shares closed at$7.97 on Wednesday. See how other analysts view this stock.RBC Capital analyst Walter Spracklin upgraded the rating for CSX Corporation CSX from Sector Perfo ...